Gapping up
In reaction to strong earnings/guidance: INCR +6.8%, BPOP +4.3%, LH +2.8%, QSR +1%, INGN +0.9%, CYOU +0.6%
M&A news: IGTE +3.4% (to be acquired by Capgemini (CGEMY) for $48 per share), PWRD +3.3% (enters into definitive agreement for going private transaction),HSBC +2.9% (SundayTimes details news that HSBC (HSBC) may consider EUR 20 bln spinoff of Britain retail unit), CELG +1% (to acquire Quanticel Pharma for an upfront payment of $100 mln in cash plus contingent payments; sees deal neutral to adj. FY15 earnings)
Other news: SYMX +66.7% (Paulson & Co discloses 11.7% passive stake in 13G filing), CANF +23% (reports positive results from further analysis of Phase II/III Psoriasis trial; Data suggest CF101 as potential first-line systemic therapy for patients with moderate-severe psoriasis), NBG +5.7% (ongoing volatility on Greece default), LXU +4.1% (LSB Industries and Starboard Value reach agreement regarding corporate governance and board composition), CBLI +3.8% (announces the award of a 3-year, $1.2 mln Breast Cancer Research Program Award to Roswell Park from the Department of Defense Congressionally Directed Medical Research Program for research into the immunotherapy of metastatic breast cancer), ZIOP +3.1% ( Initiation of Phase 1b/2 Study of Ad-RTS-hIL-12 Gene Therapy), TSL +2.5% (signs strategic cooperation agreement to develop up to 300 MW of distributed generation solar power and related projects in Hefei, Anhui Province), AXTA +2.2% (signed agreement with Rheinmetall MAN Military Vehicles Australia to provide coating products for over 2,500 Australian military logistic vehicles), MACK +2.2% (Merrimack Pharma and Baxter BioScience announce completion of new drug application submission to U.S. FDA for MM-398 as a treatment for post-gemcitabine metastatic pancreatic cancer), GWPH +2.1% (announces that the USPTO has issued a Notice of Allowance for a patent application which covers the use of cannabidivarin for treating epilepsy; also TechCrunch discusses upcoming changes to marijuana industry), ACHN +2% (presents detailed clinical results on ACH-3102 and ACH-3422 at the International Liver Congress), NVO +1.9% (among EMA recommendations on extensions of therapeutic indication), ASML +1.9% (cont strength), CPRX +1.6% (slight rebound following last weeks decline), AAPL +1.6% (report earnings later today, positive view at Barrons), PHG +1.1% (set to report earnings tonight), RCL +1% (cont strength)
Analyst comments: TRUE +5% (upgraded to Buy from Neutral at Goldman), NBR +3.7% (upgraded to Buy from Neutral at Goldman), YPF +2.8% (upgraded to Overweight from Neutral at JP Morgan), PTEN +2.1% (upgraded to Buy from Neutral at Goldman), JD +2.1% (initiated with a Overweight at JP Morgan), NEM +1.5% (upgraded to Outperform from Neutral at Credit Suisse), DIS+1.1% (upgraded to Buy from Neutral at Guggenheim
)
In reaction to strong earnings/guidance: INCR +6.8%, BPOP +4.3%, LH +2.8%, QSR +1%, INGN +0.9%, CYOU +0.6%
M&A news: IGTE +3.4% (to be acquired by Capgemini (CGEMY) for $48 per share), PWRD +3.3% (enters into definitive agreement for going private transaction),HSBC +2.9% (SundayTimes details news that HSBC (HSBC) may consider EUR 20 bln spinoff of Britain retail unit), CELG +1% (to acquire Quanticel Pharma for an upfront payment of $100 mln in cash plus contingent payments; sees deal neutral to adj. FY15 earnings)
Other news: SYMX +66.7% (Paulson & Co discloses 11.7% passive stake in 13G filing), CANF +23% (reports positive results from further analysis of Phase II/III Psoriasis trial; Data suggest CF101 as potential first-line systemic therapy for patients with moderate-severe psoriasis), NBG +5.7% (ongoing volatility on Greece default), LXU +4.1% (LSB Industries and Starboard Value reach agreement regarding corporate governance and board composition), CBLI +3.8% (announces the award of a 3-year, $1.2 mln Breast Cancer Research Program Award to Roswell Park from the Department of Defense Congressionally Directed Medical Research Program for research into the immunotherapy of metastatic breast cancer), ZIOP +3.1% ( Initiation of Phase 1b/2 Study of Ad-RTS-hIL-12 Gene Therapy), TSL +2.5% (signs strategic cooperation agreement to develop up to 300 MW of distributed generation solar power and related projects in Hefei, Anhui Province), AXTA +2.2% (signed agreement with Rheinmetall MAN Military Vehicles Australia to provide coating products for over 2,500 Australian military logistic vehicles), MACK +2.2% (Merrimack Pharma and Baxter BioScience announce completion of new drug application submission to U.S. FDA for MM-398 as a treatment for post-gemcitabine metastatic pancreatic cancer), GWPH +2.1% (announces that the USPTO has issued a Notice of Allowance for a patent application which covers the use of cannabidivarin for treating epilepsy; also TechCrunch discusses upcoming changes to marijuana industry), ACHN +2% (presents detailed clinical results on ACH-3102 and ACH-3422 at the International Liver Congress), NVO +1.9% (among EMA recommendations on extensions of therapeutic indication), ASML +1.9% (cont strength), CPRX +1.6% (slight rebound following last weeks decline), AAPL +1.6% (report earnings later today, positive view at Barrons), PHG +1.1% (set to report earnings tonight), RCL +1% (cont strength)
Analyst comments: TRUE +5% (upgraded to Buy from Neutral at Goldman), NBR +3.7% (upgraded to Buy from Neutral at Goldman), YPF +2.8% (upgraded to Overweight from Neutral at JP Morgan), PTEN +2.1% (upgraded to Buy from Neutral at Goldman), JD +2.1% (initiated with a Overweight at JP Morgan), NEM +1.5% (upgraded to Outperform from Neutral at Credit Suisse), DIS+1.1% (upgraded to Buy from Neutral at Guggenheim
)